In 1992, an endocrinologist at a Veterans Affairs hospital in the Bronx was buying lizard venom through the mail. Dr. John Eng had a hunch about Gila monsters. They eat a few enormous meals a year and then idle for months, which means their blood sugar machinery has to work on a timescale ours does not. Dr. Eng found what he was looking for: a peptide, exendin-4, that behaved almost exactly like a human hormone called GLP-1, and differed from it at the second position in the chain by a single amino acid. An enzyme in our blood recognizes that spot and snips two amino acids off the front, switching the hormone off in about two minutes. The lizard's carries a different amino acid there, the enzyme cannot get a grip, and the signal stays open for hours.

That is the entire idea behind a class of drugs you have heard a great deal about lately that control the signal the gut sends after a meal to release insulin and register fullness. The first one to market came more or less directly out of the venom. The ones after it are synthetic, but the thing the lizard proved is the load-bearing insight underneath all of them. It is now one of the largest revenue streams in the history of medicine.

The Gila monster is listed as near threatened. Its range is being cut apart by development across the Sonoran Desert. It has received nothing.

This is not an unusual story. It is closer to the standard one.

The rosy periwinkle, a small pink flower from Madagascar, yielded vinblastine and vincristine, which turned childhood leukemia from a death sentence into something survivable — the survival rate went from roughly one in ten to roughly nine in ten. Eli Lilly brought them to market. Madagascar, one of the poorest countries on earth and one of the most biologically irreplaceable, has never seen a royalty.

The Pacific yew, a scrubby understory tree loggers used to burn as slash, turned out to hold paclitaxel, and became a multibillion-dollar cancer drug for Bristol-Myers Squibb. A Brazilian pit viper's venom, which kills by collapsing blood pressure, gave Sérgio Ferreira, a Brazilian pharmacologist, the peptide that Squibb turned into captopril, opening the entire modern category of blood-pressure medicine. In every case the organism did the research. Millions of years of it, at enormous cost, with a failure rate we would find unbearable.

We have a name for the arrangement — bioprospecting. Prospecting is what you do on ground that "belongs to nobody".

What's strange is that we are not bad at credit. We are extravagantly, obsessively good at it. A patent must cite its prior art under what the law calls a duty of candor, and the citation is legally consequential. An academic paper carries a tail of references longer than some of its arguments. A film ends with eight minutes of names, including the people who fed everyone. A song's royalties are split to four decimal places among writers, publishers, performers and estates, and there is an entire profession devoted to arguing about those decimals. We built attribution infrastructure of a sophistication that would have astonished any previous century, and we maintain it at real expense.

None of that machinery is broken. It works. It just has one assumption welded into it: that a contributor is a person.

Then someone tested that assumption.

Since 2024, NATURE has been a verified artist on Spotify, Apple Music, Amazon Music and Deezer — the first non-human one. The project behind it is called Sounds Right, and it came out of the Museum for the United Nations, with the design work done by the agency AKQA. Musicians who use ecosystem recordings in a track can credit NATURE as a featured artist, and when they do, a share of the recording royalties goes to EarthPercent, a registered charity that pays it out to conservation work, weighted toward Indigenous and community-led projects in biodiversity hotspots. Sounds Right won the top innovation prize at Cannes, and everyone covered it as a lovely gesture.

Look at what Sounds Right actually did, though. It did not build a donation portal. It did not launch a campaign with a progress bar, or a limited-edition drop, or a partnership microsite. It put a name in a field that already existed: contributor.

And everything attached to that field came along for free: the royalty split, the payee record, the recurring payment rail, the verified page, the monthly listener count, the algorithmic surfacing, the fact that a stream in 2031 still pays. None of that had to be designed, argued for, or funded. It was already sitting there, fully built, load-tested by decades of use. Nobody had tried to put something non-human in the box, so nobody had discovered that the box didn't care.

I want to be honest about the scale.

The projections talked about forty million dollars over four years. The first year's streams committed two hundred and twenty-five thousand, split across four programs in the Tropical Andes: Reserva Natural La Planada, Fundación Proyecto Tití, FundaExpresión, Jacana Jacana. That is about two percent of the annual pace the projection implied, and anyone telling you a Spotify credit is going to fund the defense of the Andes is selling something. A few hundred thousand dollars does not save an ecosystem.

But it was never going to be a fundraiser, and judging it as one misses what happened. What happened is that a payee slot in a global financial system now contains something that is not a person and not a company, and it has been sitting there for two years, paying out on schedule, without anything breaking. The money is a receipt proving the precedent is real.

So, where else does naming a contributor already move money?

One has been sitting in plain sight so long it has become invisible. Trademarks.

Amazon is named after the river. Not metaphorically — Bezos picked it because it was the biggest one. That name now sits on a company worth more than most national economies, and the rainforest that lent it has been shrinking the entire time. Fiji Water pumps an actual Fijian aquifer and sells it worldwide, and when Fiji once tried to raise the tax on the water leaving the island, the company shut the plant and laid off its workforce. Every outdoor brand named after a mountain range, every car named after a big cat, every beer named after a river, every tech company that took an animal's name because it wanted the animal's qualities — falcon, puma, jaguar, cobra, impala — is running an unlicensed endorsement deal with a party that cannot negotiate.

Trademark licensing is not a new or fragile mechanism. It is one of the most mature royalty rails we have, with standard rates, standard contracts, and centuries of case law. A brand built on a place or a species could route a fraction of a percent to that place or that species with paperwork that already exists, on a template a licensing lawyer could fill out before lunch.

Patagonia is the one that half-answers this, and it's worth noticing exactly how. Since 1985 it has given a percentage of sales away, and in 2022 its founder restructured ownership so the profits fund environmental work in perpetuity. That is the closest thing we have to a brand paying rent on its own name — and it required a billionaire to voluntarily give away his company, which is not a mechanism. It is a miracle. The point of a royalty rail is that it works when nobody involved is a saint.

Then there are the mascots, which sound like a joke until you look at the numbers.

American professional sports have made a fortune off animals: lions, bears, eagles, panthers, dolphins, ravens, bengals, timberwolves. Merchandising alone runs into the billions annually, and a meaningful share of it is species imagery on fabric. The Detroit Lions have outlasted lions in most of their historical range — the species has lost something on the order of nine-tenths of it. The eastern cougar, the panther of the eastern United States, was formally declared extinct in 2018; the Carolina Panthers went on selling jerseys. The team's foundation gives real money, every year, to youth programs across the Carolinas — its stated purpose. Nothing in it points at a cat. The bald eagle is the more positive case, because it is the one where the machinery of protection actually ran, and it recovered, and in 2024 it was finally made the official national bird after two centuries of being on everything anyway.

A licensing fee of a fraction of one percent on mascot merchandise, routed to the species on the jersey, would dwarf what the entire music initiative will ever raise. It would require no new law, no new institution, and no consumer behavior change whatsoever. It would require one clause in a merchandising contract.

And for the pharmaceutical case that opened this — the lizard, the periwinkle, the yew — the mechanism now exists.

Under the Convention on Biological Diversity, governments agreed to something called the Cali Fund, launched in early 2025. Companies commercially exploiting genetic sequence data — pharma, cosmetics, agricultural biotech, and explicitly the AI services built on that data — are asked to contribute one percent of profits or a tenth of a percent of revenue. At least half of what comes in goes to Indigenous peoples and local communities. Its first contribution arrived at the end of 2025, and its problem right now is not architecture but participation: the rail is built and mostly empty.

None of this is really about nature. It is about who a system lets you name.

Every field in every system is a compressed argument about what exists and who counts, made once, and then enforced by the software forever after. Nobody has to forbid paying the forest. The form simply has no line for it. After enough years a missing line stops looking like a choice somebody made and starts looking like the way the world is.

This is the ordinary condition of most systems, including every one I have worked on. The defaults are the argument for simplicity. The dropdown is the worldview. The set of things that can appear in the payee column is a claim about who can get paid.

Which means the intervention is often much smaller than the problem suggests. Not a campaign. Not awareness. Not a new platform to compete with the ones that exist. Find the rail that already moves money on schedule, at scale, with legal force behind it, and find the field on that rail that nobody thought to use in service of nature.

Somebody looked at the featured-artist credit on a streaming platform, a field designed so a rapper could bring in a singer, and realized that the form does not ask what you are. Two years later a payment goes out every month to a rainforest.

The lizard is still owed. But the field was never locked. It was only ever empty, and we mistook empty for closed.